OmniAb, Inc. (OABI) Stock Price & Analysis
OmniAb, Inc. (OABI) closed at USD 5.28 on Wednesday, October 28, 2026, up 6.45% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 4.96; the Oct 28, 2026 session ranged USD 4.91–5.29 on volume of 1,582,653 shares. Market capitalization is $767.66M, with a 52-week range of USD 1.3–5.43 (NGM). Source: Nexqual, retrieved October 29, 2026 at 07:28 UTC.
Also available as compact Markdown for AI agents: nexqual.com/OABI.md
Key facts (OABI)
- Last four reported quarters (through Jun 30, 2026): revenue $38.5M, net income -$44.3M (-115.1% margin), free cash flow -$18.1M (SEC filings).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (7 analysts), mean target USD 8.33 (range 5–12).
- Total return with dividends: 1Y +259.2% vs S&P 500 +13.6%; 5Y -47.1% vs S&P 500 +79.8%.
- Next earnings: 2026-10-30, EPS estimate USD -0.13, revenue estimate $3.5M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (OABI)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $34.7M | $59.1M | $34.2M | $26.4M | $18.7M | $38.5M |
| Operating income | -$35.6M | -$26.6M | -$69.4M | -$74.5M | -$69.0M | -$48.4M |
| Net income | -$27.0M | -$22.3M | -$50.6M | -$62.0M | -$64.8M | -$44.3M |
| EPS (diluted) | -$0.33 | -$0.26 | -$0.51 | -$0.61 | -$0.57 | — |
| Free cash flow | -$9.7M | -$20.8M | $703K | -$41.5M | -$37.0M | -$18.1M |
| Operating margin | -102.5% | -45.1% | -203.2% | -282.3% | -369.5% | -125.8% |
| Net margin | -77.8% | -37.8% | -148.2% | -235.1% | -347.0% | -115.1% |
| Revenue growth | — | +70.0% | -42.2% | -22.8% | -29.3% | — |
| Cash + short-term investments | $0K | $88.3M | $87.0M | $59.4M | $54.0M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (OABI)
P/S 20.0x · P/B 3.0x · FCF yield -2.36% · Earnings yield -5.77%
Analysts (OABI)
Consensus Buy (mean 2.00 on a 1–5 scale), 7 analysts; mean target USD 8.33 (low 5, high 12).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Leerink Partners | Target raised | Outperform | $10 → $12 |
| 2026-10-07 | StoneX | Target raised | Buy | $4 → $6 |
| 2026-08-17 | HC Wainwright & Co. | Reiterated | Buy | $11 |
Total return (dividends reinvested) (OABI)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +259.2% | -47.1% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +260.8% | -11.9% |
| Volatility (annualized) | 72.4% | 78.8% |
| Max drawdown | -37.0% (Dec 2025→Apr 2026) | -87.7% (Oct 2022→May 2025) |
OABI earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.05 | −$0.13 | Beat +61.5% | — |
| — | Quarter ended Mar 31, 2026 | −$0.06 | −$0.10 | Beat +40.0% | — |
| — | Quarter ended Dec 31, 2025 | −$0.11 | −$0.09 | Miss −22.2% | — |
| — | Quarter ended Sep 30, 2025 | −$0.14 | −$0.14 | In line | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
OABI recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Aug 14, 2026 | Schedule 13G/A | Whitefort Capital Management, LP, David Salanic: 7.1% of shares, passive 5%+ holder (amended) |
| Aug 6, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 6, 2026 | 8-K | Quarterly results |
| Jul 13, 2026 | 8-K | Director or executive officer change, or pay arrangement “Effective July 13, 2026, Amechi Nwachuku was appointed as the Chief Operating Officer of OmniAb, Inc. (the "Company"). Mr. Nwachuku, 51, is a global life sciences executive with more than two decades of leadership experience spanning life sciences tools, biotechnology, diagnostics, pharmaceuticals, medical devices, and consumer health. Most recently, from May 2024 to April 2025, Mr. Nwachuku served as Vice President, Global Commercial, Genetic Sciences at Thermo Fisher Scientific. From August 2021 to June 2023, he…” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
OABI revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| License and milestone revenue | $9.5M | 70.9% | +666.1% |
| Service revenue | $2.5M | 18.4% | +27.7% |
| xPloration revenue | $1.2M | 8.7% | +91.0% |
| Royalty revenue | $266,000 | 2.0% | +139.6% |
| Total revenue | $13.4M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
OABI suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Competitor | WuXi | “•in ion channel drug discovery, we face technical competition from companies that provide similar technologies, or biological expertise, such as Charles River Labs Inc., Evotec SE, Metrion Biosciences Ltd., and WuXi AppTec.” |
Quoted from the company's 10-K filed Mar 4, 2026.
Companies that name OABI in their SEC reports
| Relationship to OABI | Company | Filing | Sentence |
|---|---|---|---|
| partner | ALX ONCOLOGY HOLDINGS INC (ALXO) | 10-K Mar 9, 2026 | “In March 2017, the Company entered into an agreement with Crystal Bioscience Inc. (now a subsidiary of OmniAb, Inc.), or Crystal, under which the Company obtained an assignment of certain patents, covering certain SIRPα antibodies.” |
OABI customer concentration
In the period ended Dec 31, 2025, 3 direct customers each accounted for at least 10% (15%, 12%, 10%) of revenue, per the company's 10-K filed Mar 4, 2026. The company does not name them.
OABI analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.13 | $-0.12 | −$0.01 | $3.5M | 4 |
| Next quarter (ends Dec 2026) | $-0.14 | $-0.11 | −$0.02 | $3.8M | 4 |
| Current fiscal year (ends Dec 2026) | $-0.37 | $-0.42 | +$0.05 | $35.0M | 5 |
| Next fiscal year (ends Dec 2027) | $-0.29 | $-0.32 | +$0.03 | $43.9M | 4 |
Key Statistics (as of October 29, 2026 at 07:28 UTC)
| Price | USD 5.28 |
|---|---|
| Change | ▲ 6.45% (up) |
| Previous Close | USD 4.96 |
| Open | USD 4.92 |
| Day Range | USD 4.91 – 5.29 |
| 52-Week Range | USD 1.3 – 5.43 |
| Volume | 1,582,653 shares |
| Market Cap | $767.66M |
| Exchange | NGM |
Technical Analysis (OABI)
Nexqual's technical model rates OABI "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 29, 2026 at 07:28 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 65.58 (neutral) |
| vs SMA50 | Above (USD 4.62) |
| MACD | 0.12 (positive) |
Analyst Ratings (OABI)
Wall Street analysts rate OABI "Buy" based on 7 analysts, with a mean price target of USD 8.33 (range USD 5–12), per Nexqual as of October 29, 2026 at 07:28 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 8.33 |
| High Target | USD 12 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (OABI)
| Next Earnings Date | 2026-10-30 |
|---|---|
| EPS Estimate | USD -0.13 |
| Revenue Estimate | $3.49M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.05 vs est -0.13 ▲ beat |
| 2026-03-31 | USD -0.06 vs est -0.1 ▲ beat |
| 2025-12-31 | USD -0.11 vs est -0.09 ▼ miss |
| 2025-09-30 | USD -0.14 vs est -0.14 ▼ miss |
Source: Nexqual, October 29, 2026 at 07:28 UTC.
Financials & Fundamentals (OABI)
| Total Revenue | $38.46M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +244.20% |
| Gross Margin | +98.28% |
| Operating Margin | -49.47% |
| Profit Margin | -115.12% |
| ROE | -16.95% |
| Debt / Equity | 0.07 |
| Current Ratio | 4.8 |
| Total Cash | $51.99M |
| Total Debt | $18.91M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$18.14M (-47.2% of revenue) |
Source: Nexqual, October 29, 2026 at 07:28 UTC.
Financial Health Score (OABI)
Nexqual rates OmniAb, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 07:28 UTC.
| Growth | Critical — Revenue -29% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $52M cash vs $19M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$18M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -17%, ROA -15.3% (last 4 quarters, SEC) |
Ownership (OABI)
| Insider Ownership | +15.28% |
|---|---|
| Institutional Ownership | +52.83% |
| Shares Outstanding | 145.39M |
| Float | 118.24M |
| Short % of Float | +6.45% |
Source: Nexqual, October 29, 2026 at 07:28 UTC.
Leadership (OABI)
OmniAb, Inc. is led by Matthew W. Foehr, President, CEO & Director, per Nexqual as of October 29, 2026 at 07:28 UTC.
| President, CEO & Director | Matthew W. Foehr |
|---|---|
| Executive VP of Finance & CFO | Kurt A. Gustafson |
| Executive VP & Chief Operating Officer | Amechi Nwachuku |
| Senior Vice President of People & Talent | Cia McCaffrey |
| Senior Vice President of Discovery Partnership Mgt., Technology Development & Operations | Bill Harriman |
Major Backers & Investors (OABI)
Notable institutional backers of OmniAb, Inc. include Whitefort Capital Management, LP, Nomura Holdings Inc., Cadian Capital Management, LP, according to Nexqual as of October 29, 2026 at 07:28 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Whitefort Capital Management, LP | 7.07% |
| Nomura Holdings Inc. | 3.47% |
| Cadian Capital Management, LP | 2.91% |
| Rice, Hall, James & Associates LLC | 1.8% |
| Private Management Group, Inc. | 1.62% |
| Fidelity | 1.24% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.14% |
| Vanguard Group | 2.66% |
| Geode Capital | 1.99% |
| State Street | 1.47% |
Source: Nexqual, October 29, 2026 at 07:28 UTC.
From OmniAb, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- At the heart of the OmniAb platform is what we call Biological IntelligenceTM, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
- We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions.
- Our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® have been genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates.
- Our proprietary technologies are joined with and leverage OmniDeep™, which is a suite of in silico, artificial intelligence ("AI") and machine learning tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities.
Partnerships
- In 2023, OmniAb entered into an agreement with mAbsolve Ltd. for its Fc-silencing platform technology, STR, which is based upon a proprietary engineered human Fc domain.
- Although our license agreements with pharmaceutical and biotechnology partners typically include technology access fees, milestone payments and royalties, each agreement is negotiated separately and as a result, the financial terms and contractual provisions vary from agreement to agreement.
Legal & Regulatory Risks (Item 1A, quoted)
- Our business could become subject to more extensive government regulation than we currently anticipate, and regulatory compliance obligations and the investigational exemption and approval processes to which our animals may become subject are expensive, time-consuming and uncertain both in timing and in outcome.
- Our business operations and current and future relationships with investigators, healthcare professionals, and partners may be subject to applicable fraud and abuse and other healthcare laws and regulations, which could expose us and/or our partners to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and future earnings.
- Changes in and actual or perceived failures to comply with applicable data privacy, security and protection laws, regulations, standards and contractual obligations may adversely affect our business, operations and financial performance.
- Changes in either the patent laws or in interpretations of patent laws in the United States or other countries or regions may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third party patents. We may not develop additional proprietary platforms, methods and technologies that are patentable.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| ABVX | Abivax SA | USD 89.84 | ▲ 3.26% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 07:28 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt